|Articles|August 10, 2009
OmniComm Systems To Provide eClinical Solutions for two Phase I HIV Studies
Advertisement
OmniComm Systems (Ft. Lauderdale, FL) announced that it has been selected by an unnamed biopharmaceutical company to provide eClinical solutions for two of its Phase I HIV studies involving over 100 patients. Both HIV studies are expected to run for seven months. The company has already used OmniComm Systems in different therapeutic areas.
OmniComm recently announced acquisitions of EDC assets of ERT and Logos Technologies.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
3
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
4
ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial
5